cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Esperion Therapeutics Inc
22 own
24 watching
Current Price
$0.99
$-0.1
(-9.16%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
117.78M
52-Week High
52-Week High
8.87000
52-Week Low
52-Week Low
0.85000
Average Volume
Average Volume
9.81M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization117.78M
icon52-Week High8.87000
icon52-Week Low0.85000
iconAverage Volume9.81M
iconDividend Yield--
iconP/E Ratio--
What does the Esperion Therapeutics Inc do?
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Read More
How much money does Esperion Therapeutics Inc make?
News & Events about Esperion Therapeutics Inc.
PR Newswire
3 months ago
Thinking about trading options or stock in Inpixon, DatChat, Esperion Therapeutics, Verastem, or Vision Marine Technologies? Thinking about trading options or stock in Inpixon, DatChat, Esperion Therapeutics, Verastem, or Vision Marine Technologies? PR Newswire NEW YORK, June 15, 2023 NEW YORK...
Globe Newswire
4 months ago
ANN ARBOR, Mich., May 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at JMP Securities Life Sciences Conference on Monday, May 15th, 2023 at 2:00 PM ET. To register for the live ...
Globe Newswire
5 months ago
Performance-Based Agreement Provides for Curraxs 72 Sales Representatives to Detail Esperions Products Reinforces Esperions Focus on Driving Persistent GrowthBy More Than Doubling Sales Team ANN ARBOR, Mich., April 19, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced an agreement ...
Zolmax
6 months ago
Esperion Therapeutics, Inc. (NASDAQ:ESPR Get Rating) CEO Sheldon L. Koenig sold 6,999 shares of Esperion Therapeutics stock in a transaction on Friday, March 17th. The shares were sold at an average price of $1.78, for a total value of $12,458.22. Following the completion of the transaction, the ...
Globe Newswire
6 months ago
ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (Esperion or the Company), today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 shares of its common stock (...
Frequently Asked Questions
Frequently Asked Questions
What is Esperion Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Esperion Therapeutics Inc shares?
plus_minus_icon
How can I buy Esperion Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Esperion Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Esperion Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Esperion Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Esperion Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Esperion Therapeutics Inc?
plus_minus_icon
What percentage is Esperion Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Esperion Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.99
$-0.1
(-9.16%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
DBV Technologies S.A.
DBV Technologies S.A.
$1.44
$0.00 (0.00 %)
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$15.70
$0.47 (3.09 %)
NATURES SUNSHINE PRODS INC
NATURES SUNSHINE PRODS INC
$16.25
$0.25 (1.56 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$1.28
$-0.06 (-4.48 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
DBV Technologies S.A.
DBV Technologies S.A.
$1.44
$0.00 (0.00 %)
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$15.70
$0.47 (3.09 %)
NATURES SUNSHINE PRODS INC
NATURES SUNSHINE PRODS INC
$16.25
$0.25 (1.56 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$1.28
$-0.06 (-4.48 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00